Table 7 Cut-off of 90% sensitivity of the markers in subjects with tPSA 4–10 ng/mL
Marker | Cut-off at 90% sensitivity | % Specificity | Unnecessary biopsy avoided | Missed cancer | |||
|---|---|---|---|---|---|---|---|
Total | Missed GS 6 | Missed GS 7 | Missed GS ≥ 8 | ||||
Total PSA 4–10 ng/mL | |||||||
%fPSA | ≤ 7.86 | 9% | 4 (5.2%) | 3 (10.3%) | 0 (0%) | 1 (3.5%) | 2 (6.8%) |
p2PSA (pg/mL) | ≥ 8.08 | 17% | 7 (9.1%) | 3 (10.3%) | 2 (6.8%) | 0 (0%) | 1 (3.5%) |
% p2PSA | ≥ 1.20 | 27% | 12 (15.5%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) |
PHI | ≥ 26.33 | 25% | 9 (11.7%) | 2 (6.8%) | 2 (6.8%) | 0 (0%) | 0 (0%) |
All study subjects | |||||||
%fPSA | ≤ 6.42 | 7% | 6 (4.3%) | 7 (11.1%) | 0 (0%) | 2 (3.2%) | 5 (7.9%) |
p2PSA (pg/mL) | ≥ 8.07 | 20% | 16 (11.4%) | 7 (11.1%) | 4 (6.3%) | 2 (3.2%) | 1 (1.6%) |
% p2PSA | ≥ 1.22 | 31% | 24 (17.1%) | 7 (11.1%) | 7 (11.1%) | 0 (0%) | 0 (0%) |
PHI | ≥ 33.40 | 40% | 32 (22.9%) | 5 (7.9%) | 5 (7.9%) | 0 (0%) | 0 (0%) |